Leukemia Clinical Trials & Research

Eytan Stein at a computer with nurse practitioner Bernadette Cuello
Program for Drug Development in Leukemia
The Program for Drug Development in Leukemia offers patients the most advanced treatments available for acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia through participation in phase 1 clinical trials.
Learn more

Over the past several years, there has been an explosion in our understanding of the pathogenesis of both acute and chronic leukemia, the number of novel agents with unique mechanisms of action, and other new strategies, including immunologic approaches. Researchers at Memorial Sloan Kettering continue to pursue these and other treatment approaches in our clinical trials. 

Relying in part on the information that is emerging about the genetic basis of leukemia, investigators are pursuing approaches that can kill tumor cells directly, inhibit the body’s production of substances that promote their growth, or enhance the immune response against leukemic cells. 

Here you can find a continually updated listing of Memorial Sloan Kettering’s current clinical trials for adults with leukemia. Our experts can help determine which clinical trial is right for you, including some of our newly opened clinical trials:

For clinical trials for children with leukemia, please visit Pediatric Clinical Trials.

You can also visit our Blood & Marrow Stem Cell Transplantation Clinical Trials.

and/or
Reset
70 Clinical Trials found
A Phase 2 Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia
Some people treated for acute myeloid leukemia (AML) with induction (initial) chemotherapy are left with minimal residual disease (MRD). With MRD, there is a small number of leukemia cells from the bone marrow remaining in the body. MRD increases the chance that the cancer will come back after a bone marrow transplant from a donor.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Azacitidine and Venetoclax Versus a Bone Marrow Transplant in People 65 Years and Older With Acute Myeloid Leukemia
Researchers are comparing bone marrow transplantation to maintenance chemotherapy as post-induction treatment in older people with acute myeloid leukemia (AML) in remission. The people in this study are 65 or older and already had azacitidine and venetoclax as induction treatment. 
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Azacitidine and Venetoclax With and Without Gilteritinib for Older and Unfit Adults With FLT3-Mutated Acute Myeloid Leukemia
Azacitidine turns on genes that help control cell growth. It is given intravenously (by vein) or by injection.
New York City, Commack, Basking Ridge, Monmouth, Bergen
A Phase 2 Study of Nivolumab Plus Standard Treatment in People With Richter's Transformation
When people have Richter's transformation, their chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) changes into a more aggressive disease. Researchers are assessing a new drug combination for people with Richter's transformation that came back or keeps growing after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Obinutuzumab, Sonrotoclax, and Zanubrutinib in People With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Researchers want to see how well the combination of obinutuzumab, sonrotoclax, and zanubrutinib works against leukemia and lymphoma. The people in this study have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not been treated.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Revumenib in People With Acute Leukemia
Researchers want to see how well revumenib works against acute leukemia. The people in this study have acute leukemia that keeps growing after treatment. They also have a mutation (change) in the HOX gene, which is related to new or immature leukemia cells.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Revumenib With Chemotherapy for Children with Recurrent or Persistent Infant Leukemia
Researchers want to see how well revumenib works when given with chemotherapy to treat infant leukemia. The children in this study have acute leukemia that came back or keeps growing even after treatment. The leukemia has a gene rearrangement (genetic change) called KMT2A-R.
New York City
A Phase 2 Study of Ruxolitinib in People With T-Cell Large Granular Lymphocytic Leukemia
Researchers want to see if ruxolitinib works well as a treatment for T-cell large granular lymphocytic leukemia (T-LGLL). T-LGLL is a rare cancer of white blood cells called lymphocytes. The people in this study have T-LGLL that keeps growing even with treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of TL-895 in People With Indolent Systemic Mastocytosis
TL-895 blocks the action of an enzyme called Bruton's tyrosine kinase (BTK). Tyrosine kinases are involved in many cell functions, including signaling, growth, and division. The activation of BTK in mast cells may trigger ISM symptoms. TL-895 is taken orally (by mouth).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Vemurafenib and Obinutuzumab Versus Cladribine and Rituximab in People With Untreated Hairy Cell Leukemia
Researchers in this study are comparing two different treatments for hairy cell leukemia. The people in this study have hairy cell leukemia that has not yet been treated. In addition, their leukemia has a genetic mutation (change) called BRAF V600E.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau